Radiance Biopharma signs exclusive license for ‘first in class’ c-Met/EGFR targeted nano antibody ADC

CAR-T Digest - August 2020

3 September 2025: Radiance Biopharma signs exclusive license for ‘first in class’ c-Met/EGFR targeted Nano antibody ADC

Radiance Biopharma signed an exclusive license agreement with Novatim Immune Therapeutics for global rights (excluding Greater China) to develop and commercialize RB-601, a first-in-class bispecific nanobody ADC targeting c-MET and EGFR
Under the deal, Radiance will pay $15M upfront, up to $150M in development and regulatory milestones, over $1B in commercial milestones, and tiered royalties, while leading development outside Greater China
RB-601 uses site-specific conjugation with a DAR of four and a tuned-down EGFR affinity to improve safety, delivering an MMAE payload that disrupts cell division upon internalization
Preclinical studies in mice and primates showed strong efficacy and safety in tumors such as NSCLC, colorectal, pancreatic, and kidney cancers, and the drug is already in a Phase 1 trial in China with INDs cleared by both NMPA and FDA
Radiance sees RB-601 as a potential best-in-class therapy, expanding its ADC pipeline and advancing its strategy to develop next-generation treatments for solid tumors with high unmet needs